Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
20/20 Biolabs Inc stock logo
AIDX
20/20 Biolabs
$0.16
-13.0%
$0.31
$0.16
▼
$50.00
$2.10MN/A230,171 shs301,482 shs
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
$1.65
-10.8%
$4.51
$1.63
▼
$80.70
$3M-1.0489,275 shs52,627 shs
INVO Fertility, Inc stock logo
IVF
INVO Fertility
$1.76
$9.07
$1.59
▼
$91.60
$2.10M2.4239,726 shs16,584 shs
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
$0.12
-7.6%
$0.32
$0.12
▼
$1.38
$2.75M2.15839,877 shs241,104 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
20/20 Biolabs Inc stock logo
AIDX
20/20 Biolabs
0.00%-23.10%-37.34%-71.66%+15,709,900.00%
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
0.00%-25.00%-47.95%-72.50%-92.52%
INVO Fertility, Inc stock logo
IVF
INVO Fertility
0.00%-32.31%-79.36%-89.62%-99.26%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
0.00%-20.26%-49.41%-70.71%-90.03%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
20/20 Biolabs Inc stock logo
AIDX
20/20 Biolabs
$0.16
-13.0%
$0.31
$0.16
▼
$50.00
$2.10MN/A230,171 shs301,482 shs
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
$1.65
-10.8%
$4.51
$1.63
▼
$80.70
$3M-1.0489,275 shs52,627 shs
INVO Fertility, Inc stock logo
IVF
INVO Fertility
$1.76
$9.07
$1.59
▼
$91.60
$2.10M2.4239,726 shs16,584 shs
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
$0.12
-7.6%
$0.32
$0.12
▼
$1.38
$2.75M2.15839,877 shs241,104 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
20/20 Biolabs Inc stock logo
AIDX
20/20 Biolabs
0.00%-23.10%-37.34%-71.66%+15,709,900.00%
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
0.00%-25.00%-47.95%-72.50%-92.52%
INVO Fertility, Inc stock logo
IVF
INVO Fertility
0.00%-32.31%-79.36%-89.62%-99.26%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
0.00%-20.26%-49.41%-70.71%-90.03%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
20/20 Biolabs Inc stock logo
AIDX
20/20 Biolabs
2.00
Hold$5.003,082.69% Upside
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
1.00
SellN/AN/A
INVO Fertility, Inc stock logo
IVF
INVO Fertility
2.50
Moderate Buy$320.0018,081.82% Upside
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest IVF, BIAF, MGRX, and AIDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
20/20 Biolabs Inc stock logo
AIDX
20/20 Biolabs
UpgradeSell (E) ➝ Sell (E+)
10/30/2026
20/20 Biolabs Inc stock logo
AIDX
20/20 Biolabs
Reiterated RatingSell (E)
10/30/2026
INVO Fertility, Inc stock logo
IVF
INVO Fertility
Reiterated RatingSell (E+)
10/16/2026
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
Reiterated RatingSell (E+)
9/21/2026
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
Reiterated RatingSell (E+)
(Data available from 11/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
20/20 Biolabs Inc stock logo
AIDX
20/20 Biolabs
$2.05M1.02N/AN/A$0.05 per share3.14
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
$6.16M0.49N/AN/A$2.15 per share0.77
INVO Fertility, Inc stock logo
IVF
INVO Fertility
$6.84M0.31N/AN/A$14.76 per share0.12
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
$315.23K8.71N/AN/A$0.62 per share0.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
20/20 Biolabs Inc stock logo
AIDX
20/20 Biolabs
-$3.74M-$0.54N/AN/AN/A-317.83%-539.40%-120.73%N/A
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
-$14.91M-$44.27N/AN/AN/A-278.90%-293.44%-160.36%N/A
INVO Fertility, Inc stock logo
IVF
INVO Fertility
-$25.13M-$135.32N/AN/AN/A-93.93%-42.94%-23.72%N/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
-$20.64M-$0.51N/AN/AN/A-3,679.33%-68.28%-62.66%N/A

Latest IVF, BIAF, MGRX, and AIDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/16/2026Q3 2026
20/20 Biolabs Inc stock logo
AIDX
20/20 Biolabs
N/A-$0.12N/A-$0.12N/A$0.38 million
11/16/2026Q3 2026
INVO Fertility, Inc stock logo
IVF
INVO Fertility
N/A-$2.44N/A-$2.44N/A$2.22 million
11/16/2026Q3 2026
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A-$0.19N/A-$0.19N/A$0.07 million
11/6/2026Q3 2026
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
-$31.50-$5.89+$25.61-$5.89$1.91 million$1.07 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
20/20 Biolabs Inc stock logo
AIDX
20/20 Biolabs
N/AN/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
N/AN/AN/AN/AN/A
INVO Fertility, Inc stock logo
IVF
INVO Fertility
N/AN/AN/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
20/20 Biolabs Inc stock logo
AIDX
20/20 Biolabs
N/A
1.62
1.95
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
0.13
1.51
1.47
INVO Fertility, Inc stock logo
IVF
INVO Fertility
0.02
1.00
0.67
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A
1.28
0.18

Institutional Ownership

CompanyInstitutional Ownership
20/20 Biolabs Inc stock logo
AIDX
20/20 Biolabs
N/A
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
1.64%
INVO Fertility, Inc stock logo
IVF
INVO Fertility
12.02%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
56.72%

Insider Ownership

CompanyInsider Ownership
20/20 Biolabs Inc stock logo
AIDX
20/20 Biolabs
27.66%
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
2.40%
INVO Fertility, Inc stock logo
IVF
INVO Fertility
0.43%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
16.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
20/20 Biolabs Inc stock logo
AIDX
20/20 Biolabs
1413.37 million9.67 millionN/A
bioAffinity Technologies, Inc. stock logo
BIAF
bioAffinity Technologies
571.82 million1.78 millionNot Optionable
INVO Fertility, Inc stock logo
IVF
INVO Fertility
461.19 million1.19 millionNo Data
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
322.22 million18.67 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

20/20 Biolabs stock logo

20/20 Biolabs NASDAQ:AIDX

$0.16 -0.02 (-13.01%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.16 +0.01 (+5.03%)
As of 11/20/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026. Both tests are run in our CAP (College of American Pathologists) accredited, CLIA (Clinical Laboratory Improvement Amendments) licensed laboratory in Gaithersburg, MD. That laboratory also hosts our Clinical Laboratory Innovation Accelerator, or CLIAx, which we believe is the country’s first shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the U.S. without the expense of establishing and operating their own, independent lab. As noted above, during the COVID-19 pandemic, we also provided COVID-19 viral testing using polymerase chain reaction, or PCR, analytical equipment in our clinical laboratory. Our legacy business also includes a pioneering field test kit for screening suspicious powders for bioterror agents known as BioCheck. As of the date of this prospectus, we generate revenue from three sources: OneTest for Cancer (primarily as a lab test in the U.S. but we also license our algorithms to overseas labs), BioCheck and from our CLIAx. For each of the nine months ended September 30, 2025 and 2024, sales of OneTest for Cancer accounted for approximately 87% of our revenues, sales of BioCheck accounted for approximately 9% of our revenues, and our CLIAx accounted for approximately 4% of our revenues. For the years ended December 31, 2024 and 2023, sales of OneTest for Cancer accounted for approximately 85% and 65% of our revenues, respectively, sales of BioCheck accounted for approximately 10% and 13% of our revenues, respectively, our CLIAx accounted for approximately 5% and 4% of our revenues, respectively, and COVID-19 testing accounted for approximately 0% and 18% of our revenues, respectively. Our principal executive offices are located in Gaithersburg, MD.

bioAffinity Technologies stock logo

bioAffinity Technologies NASDAQ:BIAF

$1.65 -0.20 (-10.81%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.39 -0.26 (-15.76%)
As of 11/20/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

INVO Fertility stock logo

INVO Fertility NASDAQ:IVF

$1.76 0.00 (0.00%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.76 0.00 (0.00%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

Mangoceuticals stock logo

Mangoceuticals NASDAQ:MGRX

$0.12 -0.01 (-7.55%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.13 +0.01 (+4.37%)
As of 11/20/2026 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.